The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Age-related macular degeneration (AMD ... for Biomedical Therapeutics and the USC Roski Eye Institute advancing a new treatment for one of the leading causes of blindness in older adults.

A clever new set of glasses may offer new hope to people with macular degeneration. By copying the structure of a fly's eyes, the specs are claimed to "fill in" the missing section of the wearer's ...

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...

Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Age-related macular degeneration (AMD), which affects about 200 million people worldwide and can result in legal blindness, impairs an area of the eye (retina) used for reading, driving and many other ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Dry Age-Related Macular Degeneration Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and ...

I had a free morning and fancied an excuse for a new pair of prescription sunglasses ... “You have early age-related macular degeneration.” When he saw my face fall, he added: “AMD ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...